Full Coverage

Novartis decides not to pursue further development of Aurograb(TM)

pharmiweb.co.uk
29-Aug-2008
        
Story Timeline:  83 days

Aurograb(TM) decision reached after Phase II results show lack of efficacy as an add -on therapy for life-threatening bacterial infections USD 235 million impairment charge to be taken in 2008 third quarter results Mycograb(TM) continues in Phase III trials for treatment of severe fungal infections Aurograb(TM) decision reached after Phase II results show lack of efficacy as an add -on therapy for life-threatening... [read full story]                    

Add Comment
Latest article on this story:

Novartis plans to book $235-million charge after dropping drug

 pharmiweb.co.uk 30-Aug-2008
First article on this story:

Novartis Abandons Development of Aurograb Antibiotic; Expects US$235 Mln Charge in Q3 - Update

 rttnews.com 29-Aug-2008
Selected publications with coverage of this story:
ibtimes.com reuters.com contractpharma.com marketwatch.com rttnews.com yahoo.com earthtimes.org euroinvestor.co.uk pharmiweb.co.uk
RELATED
Found 12 documents:

Novartis plans to book $235-million charge after dropping drug

pharmiweb.co.uk
30-Aug-2008
        

Canadian Press (delayed) - Aug. 29, 2008 BASEL, Switzerland _ Swiss pharmaceutical company Novartis AG said Friday it would take a US$235-million impairment charge in the next quarter after deciding to drop its development...

Novartis plans to book $235M charge after dropping drug

pharmiweb.co.uk
30-Aug-2008
        

BASEL, Switzerland - Swiss pharmaceutical company Novartis AG said Friday it would take a US$235-million impairment charge in the next quarter after deciding to drop its development of a new antibiotic drug. Novartis said...

Novartis Halts Work on Antibiotic

pharmiweb.co.uk
29-Aug-2008
        

Novartis Halts Work on Antibiotic |Published: August 29, 2008 Active Discussions on SmartMoney By Steve Goldstein LONDON (Dow Jones) -- Switzerland's Novartis said Friday it's going to halt development of an antibiotic...

Novartis takes $235 mln charge after stopping trial

pharmiweb.co.uk
29-Aug-2008
        

Reuters Health - Aug. 29, 2008 By Sam Cage ZURICH (Reuters) - Novartis AG stopped development of its Aurograb treatment for bacterial infections after it showed a lack of efficacy in mid-stage trials and said it would...

                   
pharmiweb.co.uk: The headquarters of Swiss pharmaceutical giant Novartis in Basel. Novartis has said it is halting research into its Aurograb treatment designed to combat bacterial infections such as the deadly MRSA bug after disappointing clinical tests. pharmiweb.co.uk

Novartis halts research on MRSA drug after poor tests (AFP)

pharmiweb.co.uk
29-Aug-2008
        

GENEVA (AFP) - Novartis said Friday it was halting research into its Aurograb treatment designed to combat bacterial infections such as the deadly MRSA bug after disappointing clinical tests. The Swiss pharmaceutical giant...

Novartis plans $235M charge after dropping drug

pharmiweb.co.uk
29-Aug-2008
        

BASEL, Switzerland - Swiss pharmaceutical company Novartis AG said Friday it would take a $235 million impairment charge in the next quarter after deciding to drop its development of a new antibiotic drug. Novartis said...

Novartis takes $235 million hit

pharmiweb.co.uk
29-Aug-2008
        

said it's halting development of Aurograb, a drug it gained the rights to by buying NeuTec Pharma in 2006. A recently completed Phase II trial showed a lack of efficacy, Novartis said. As a result, Novartis will take a...

                   

Novartis halts research on MRSA drug after poor tests

pharmiweb.co.uk
29-Aug-2008
        

GENEVA (AFP) - Novartis said Friday it was halting research into its Aurograb treatment designed to combat bacterial infections such as the deadly MRSA bug after disappointing clinical tests. The Swiss pharmaceutical giant...

Novartis Takes $235 Million Charge After Stopping Trial

pharmiweb.co.uk
29-Aug-2008
        

ZURICH (Reuters) - Novartis AG stopped development of its Aurograb treatment for bacterial infections after it showed a lack of efficacy in mid-stage trials, and said it would take a $235 million impairment charge. The...

Novartis takes $235 million charge after stopping trial

pharmiweb.co.uk
29-Aug-2008
        

ZURICH (Reuters) - Novartis AG stopped development of its Aurograb treatment for bacterial infections after it showed a lack of efficacy in mid-stage trials, and said it would take a $235 million impairment charge. The...

1 2 next